Remdesivir, although approved by the Food and Drug Administration (FDA) in the United States as an antiviral for SARS-COV2, has been questioned due to its limited clinical effect [17], The current focus has been directed towards the complications associated with Covid-19: ARDS and Cytokine Release Syndrome, both characterized by an increase in tumor necrosis factor-alpha (TNF alpha), interleukin (IL) 1B, IL-2 IL- 6, IL-8, IL-10, and interferon y (IFN y) [18] that generate a dysregulated autoinflammatory response, severe tissue and systemic inflammation, and eventually death. This evidence concerns the gene IL10 and acute respiratory distress syndrome.